Autoimmune Decoded
Schedule time with our experts
Join Precision in Orlando
Precision for Medicine is excited to attend ACR Convergence 2026 in Orlando, Florida. Bringing together leaders across research, clinical care, and industry, this flagship rheumatology conference highlights the latest advances in rheumatic disease science and treatment.
For teams advancing therapies in rheumatic and autoimmune diseases, success depends on the right translational strategy, biomarker approach, and operational expertise. If you're developing a rheumatology or immunology program, we'd welcome the opportunity to connect.
Drop by our booth #2017 or complete the form below to schedule dedicated time with our team in Orlando.
Precision experts at ACR 2026
Connect with our ex-FDA regulatory strategists, clinical and translational specialists and rheumatology medical experts at the Precision booth.
-
Daisy DeWeese-Gatt
President, Clinical Solutions
(SizeLimitingPyList: [linkedin]) -
Harpreet Singh, MD
Chief Medical Officer and ex-FDA Division Director
(SizeLimitingPyList: [linkedin]) -
Deborah Phippard, PhD
Chief Scientific Officer
(SizeLimitingPyList: [linkedin]) -
Joy Carson
Vice President, Autoimmune Strategy
(SizeLimitingPyList: [linkedin]) -
Kader Gedik, MD
Medical Director, Autoimmune
(SizeLimitingPyList: [linkedin])
Over 20 years of Precision. Right on time for autoimmune drug development.
Built to integrate biomarker science and clinical development from the start, our established autoimmune experience in the lab and deep expertise in precision medicine clinical studies for oncology and rare diseases are crucial to autoimmune development now. New targeted therapies demand greater integration of clinical, laboratory and translational expertise.
300
Autoimmune projects
70
Full service trials
36
Autoimmune patients
400
Advanced therapy projects
Autoimmune decoded
Explore the evidence from every angle.
Talk to an Expert-
Case Study
Developing and Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays
Download Case Study
-
Case Study
Use of Epiontis ID® to support understanding therapeutic efficacy in a phase 2 psoriasis trial
Download Case Study
Curated insights
Whether you're planning an early autoimmune program, optimizing a biomarker-driven trial, or looking for integrated labs and biospecimen support, our team of experts will be at ACR 2026 and ready to connect.
Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence
